Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis. (Q48464565)

From Wikidata

Jump to navigation Jump to search

scientific article published on 16 June 2007

Language	Label	Description	Also known as
English	Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis.	scientific article published on 16 June 2007

Statements

scholarly article

1 reference

Europe PubMed Central

11 February 2018

http://europepmc.org/abstract/MED/17572882

0 references

Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis. (English)

1 reference

Europe PubMed Central

11 February 2018

http://europepmc.org/abstract/MED/17572882

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

meta-regression

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

attention deficit hyperactivity disorder

1 reference

based on heuristic

inferred from title

author name string

Jackie Y W Cheng

1

1 reference

Europe PubMed Central

11 February 2018

http://europepmc.org/abstract/MED/17572882

Ronald Y L Chen

2

1 reference

Europe PubMed Central

11 February 2018

http://europepmc.org/abstract/MED/17572882

John S N Ko

3

1 reference

Europe PubMed Central

11 February 2018

http://europepmc.org/abstract/MED/17572882

Emil M L Ng

4

1 reference

Europe PubMed Central

11 February 2018

http://europepmc.org/abstract/MED/17572882

publication date

16 June 2007

1 reference

Europe PubMed Central

11 February 2018

http://europepmc.org/abstract/MED/17572882

number of pages

13

1 reference

based on heuristic

inferred from page(s)

Psychopharmacology

1 reference

Europe PubMed Central

11 February 2018

http://europepmc.org/abstract/MED/17572882

194

1 reference

Europe PubMed Central

11 February 2018

http://europepmc.org/abstract/MED/17572882

197-209

1 reference

Europe PubMed Central

11 February 2018

http://europepmc.org/abstract/MED/17572882

2

1 reference

Europe PubMed Central

11 February 2018

http://europepmc.org/abstract/MED/17572882

https://scigraph.springernature.com/pub.10.1007/s00213-007-0840-x

0 references

Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders

1 reference

https://api.crossref.org/works/10.1007%2FS00213-007-0840-X

21 January 2018

What's wrong with Bonferroni adjustments

1 reference

https://api.crossref.org/works/10.1007%2FS00213-007-0840-X

21 January 2018

Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1007%2FS00213-007-0840-X

21 January 2018

Effect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: a meta-analysis of controlled clinical trial data

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Social impairment in girls with ADHD: patterns, gender comparisons, and correlates

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Severe liver injury after initiating therapy with atomoxetine in two children.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Obsessive compulsive disorder

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Which boys respond to stimulant medication? A controlled trial of methylphenidate in boys with disruptive behaviour

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An open-label trial of tomoxetine in pediatric attention deficit hyperactivity disorder

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Side effects of methylphenidate and desipramine alone and in combination in children

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comorbidity of attention-deficit/hyperactivity disorder with psychiatric disorder: an overview

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: the Multimodal Treatment Study of children with Attention-deficit/hyperactivity disorder

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multicenter, randomized, open-label study of OROS methylphenidate versus atomoxetine: treatment outcomes in African-American children with ADHD.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comorbid oppositional defiant disorder and the risk of relapse during 9 months of atomoxetine treatment for attention-deficit/hyperactivity disorder

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Discrimination of DSM-IV and latent class attention-deficit/hyperactivity disorder subtypes by educational and cognitive performance in a population-based sample of child and adolescent twins

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gender differences in ADHD: a meta-analysis and critical review

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Response to methylphenidate in children with ADHD and comorbid anxiety

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Atomoxetine-induced hepatitis in a child.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ADHD comorbidity findings from the MTA study: comparing comorbid subgroups

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improvement in health-related quality of life in children with ADHD: an analysis of placebo controlled studies of atomoxetine

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 year

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Methylphenidate and desipramine in hospitalized children: I. Separate and combined effects on cognitive function.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Families of children with attention-deficit/hyperactivity disorder: review and recommendations for future research

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fluoxetine monotherapy in attention-deficit/hyperactivity disorder and comorbid non-bipolar mood disorders in children and adolescents

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Depressive disorders

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Social functioning and emotional regulation in the attention deficit hyperactivity disorder subtypes

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Attention-deficit hyperactivity disorder and problems in peer relations: predictions from childhood to adolescence.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Differential effects of methylphenidate on working memory in ADHD children with and without comorbid anxiety.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A double-blind placebo controlled study of desipramine in the treatment of ADD: III. Lack of impact of comorbidity and family history factors on clinical response

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of anxiety on cognition, behavior, and stimulant response in ADHD.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Psychiatric comorbidity and response to two doses of methylphenidate in children with attention deficit disorder

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fluoxetine and methylphenidate in combination for treatment of attention deficit disorder and comorbid depressive disorder

1 reference

https://pubmed.ncbi.nlm.nih.gov/17572882

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00213-007-0840-X

1 reference

Europe PubMed Central

11 February 2018

http://europepmc.org/abstract/MED/17572882

1 reference

Europe PubMed Central

11 February 2018

http://europepmc.org/abstract/MED/17572882

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48464565&oldid=2126783556"